GSK looks to stand out in the severe asthma space with at-home injections for kids 6 to 11 years old

GlaxoSmithKline’s blockbuster Nucala may have been the first IL-5 drug to win marketing approval in severe asthma back in 2015, but newer rivals like AstraZeneca’s Fasenra have turned up the heat in recent years. Now GSK’s hoping an easier route of administration for kids will help set it apart from the pack.